Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 23: IRONMAN: Anemia, Iron Deficiency and Quality of Life
Author(s): Paul Kalra Added: 1 year ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562). The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and… View more

Heart Failure
HFA 23: TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure
Author(s): Stephen J Greene Added: 1 year ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813). The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across… View more

Heart Failure
HFA 23: MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring
Author(s): Jasper J Brugts Added: 1 year ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672). MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of… View more

Heart Failure
ACC 25 Late-Breaking Discussion: The STRIDE Trial
Author(s): Harriette Van Spall , Marc P Bonaca Added: 1 month ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The FRESH-UP Trial
Author(s): Harriette Van Spall , Roland RJ van Kimmenade Added: 1 month ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,… View more

Heart Failure
ESC 24: SHAM-PVI: Sham Study of Pulmonary Vein Isolation in Symptomatic Atrial Fibrillation
Author(s): Rick Veasey Added: 8 months ago
ESC Congress 24 — SHAM-PVI study finds pulmonary vein isolation effective in reducing atrial fibrillation (AF) episodes, improving quality of life.We are joined onsite by Dr Rick Veasey (Eastbourne District General Hospital, Eastbourne, UK) to discuss the findings from a SHAM-PVI, a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (NCT04272762; East… View more

Electrophysiology & Arrhythmia
ESC-HFA 2023: Late-Breaking Science Video Collection
Author(s): Jasper J Brugts , Ahmad Masri , Marianna Fontana , et al Added: 1 year ago
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023. Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series. For concise and practical take-home messages for practice and cardiovascular research… View more

Guidelines & Statements

Heart Failure
HFA 24: MONITOR-HF Subgroup Analysis
Author(s): Jasper J Brugts Added: 1 year ago
HFA 24 - We are joined by Dr Jasper J Brugts (Erasmus University Medical Centre, NL) to discuss the findings of a predefined subgroup analysis of the MONITOR-HF study (NTR7672).MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation,… View more

Heart Failure